Evidence map›Paper›PMID 32408197›Full record

ArticleCellular immunology2020

B cell depletion in murine lupus using cytotoxic T lymphocytes in vivo: Feasibility and benefit.

Kateryna Soloviova, Irina Puliaeva, Maksym Puliaiev, Roman Puliaev, Charles S Via

Open access · greenAbstract read
In one paragraph

Article in Cellular immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Kateryna SoloviovaDepartment of Pathology, Uniformed Services University, Bethesda, MD 20814, United States.
Irina PuliaevaDepartment of Pathology, Uniformed Services University, Bethesda, MD 20814, United States.
Maksym PuliaievDepartment of Pathology, Uniformed Services University, Bethesda, MD 20814, United States.
Roman PuliaevDepartment of Pathology, Uniformed Services University, Bethesda, MD 20814, United States.
Charles S ViaDepartment of Pathology, Uniformed Services University, Bethesda, MD 20814, United States. Electronic address: charles.via@usuhs.edu.
Uniformed Services University of the Health Sciences · US

Funding

IMMUNOPATHOGENESIS OF LUPUSR01AI047466 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI VIA, CHARLES S. · 2001 to 2012
$3.2M
Immunopathogenesis of LupusR56AI047466 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI VIA, CHARLES S. · 2014 to 2014
$189k
NIAID NIH HHS R01 AI047466NIAID NIH HHS R56 AI047466
6 · The paper itself

Abstract

Given the promising results in human lupus with B cell depletion, we tested whether in vivo cytotoxic T lymphocyte (CTL) could eliminate autoreactive B cells in the setting of murine lupus. Using the parent-into-F1 (P → F1) model to generate CTL that eliminate B cells, we found that transfer ofNZB parental splenocytes into lupus-prone female NZB/W F1 mice resulted in profound B cell reduction whereas NZW → F1 mice exhibited defective B cell elimination. Using pre-disease or early disease B/W mice as hosts, NZB → F1 mice exhibited B cell depletion and improved proteinuria but no improvement in survival whereas NZW → F1 mice had significantly reduced proteinuria and prolonged survival. Thus, despite the defective IL-2 environment in B/W F1 mice, generation of CTL and B cell depletion is feasible in NZB → F1 mice. The surprising increase in survival for NZW → F1 mice despite defective B cell elimination suggests that NZW splenocytes may contain a beneficial down regulatory cell.

Indexed as

AnimalsAutoantibodiesAutoimmunityB-LymphocytesDisease Models, AnimalFeasibility StudiesFemaleLupus Erythematosus, SystemicMaleMiceMice, Inbred NZBT-Lymphocytes, CytotoxicAutoantibodiesGraft-vs.-host diseaseLupusParent-into-F1T cells

Identifiers

PMID32408197
PMCPMC7345861
OpenAlexW3022364634

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.